Drug Profile
Danuglipron - Pfizer
Alternative Names: Danuglipron tromethamine; PF-06882961; PF-06882961 tromethamine; PF-06882961-82Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics; Benzimidazoles; Carboxylic acids; Fluorinated hydrocarbons; Obesity therapies; Piperidines; Pyridines; Small molecules
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Obesity in Belgium (PO, Tablet)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in USA (PO, Controlled release)
- 03 Dec 2023 Efficacy and adverse events data from a phase II trial in Obesity released by Pfizer